|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||21.88|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
In the first half of 2017, Roche’s (RHHBY) Xolair reported revenues of CHF 866.0 million, which is a 17.0% rise on a YoY (year-over-year) basis.
In the first half of 2017, Roche’s (RHHBY) Rituxan/MabThera reported revenues of CHF 3.8 billion, which is a 3.0% rise on a YoY basis.
In 1H17, Novartis’s (NVS) subsidiary Sandoz reported revenues of around $4.9 billion, which is a 3% decline on a year-over-year (or YoY) basis.